It's more important than ever before for your elected officials to hear from you - don't miss your chance to turn Capitol ...

In a new study, researchers examined herbal supplements with immune-activating properties that could trigger or worsen ...

Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...

As with the intravenous form, subcutaneous anifrolumab shows clinically meaningful benefits and favorable safety when added ...

Subcutaneous anifrolumab (Saphnelo) added to standard therapy significantly improves treatment outcomes in patients with ...

Telitacicept, a dual inhibitor of the cytokines B-lymphocyte stimulator and a proliferation-inducing ligand, showed efficacy ...

The total market size of systemic lupus erythematosus is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research of therapies such as nipocalimab (Johnson & ...

J&J's phase IIb JASMINE study on nipocalimab meets key endpoints in systemic lupus erythematosus, supporting plans to advance ...

USA: Researchers have reported that low vitamin D levels are strongly linked to a higher risk of death and cardiovascular ...

Which of the statements about the 2025 American College of Rheumatology guideline for the treatment of systemic lupus ...

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that predisposes affected individuals to an elevated risk of cardiovascular disease (CVD). The intricate interplay of traditional ...